Organized by:
ISD_Mainidentifier_RGB_transparent.fw.pn
MOTAC_Logo_Jata - EN.PNG
MSIDC logo transparent.fw.png
Supported by:
myceb_logo_180mm_FC_RGB.jpg
ISID Logo

9 Babcock Street, Unit 3

Brookline, MA 02446

United States

info@isid.org

Tel: +1 (617) 277-0551

Fax: +1 (617) 278-9113

  • White Facebook Icon
  • White Twitter Icon

© 2019 International Society for Infectious Diseases

SPONSORED SYMPOSIA

Industry Sponsored Symposia are commercially sponsored sessions held in conjunction with the 19th International Congress on Infectious Diseases. Sessions are open to all registered congress attendees at no charge. 

 

Note: Attending this session does not earn Continuing Education (CE) credits.

Friday, February 21, 2020

......................................................................................................................................................................

PPSV23: Still Relevant in a PCV World

Room: Banquet Hall

Friday, February 21, 2020, 10:30 – 12:00 hrs

(Organized and Sponsored by MSD)

 

  • Welcome and Introduction

  • Residual Adult Pneumococcal Disease in the Age of PCVs

  • Unraveling the Truth and Myths Behind PPSV23 Effectiveness Against Pneumococcal Pneumonia in Adults

  • A Review of Recent Evidence Supporting PPSV23 Effectiveness Against Pneumococcal Pneumonia

  • Question & Answers Panel Discussion

A Vaccine Candidate for Dengue Prevention – Updates on Takeda's Tetravalent Dengue Vaccine

Room: Conference Hall 1

Friday, February 21, 2020, 12:30 – 13:45 hrs

(Organized and Sponsored by Takeda)

 

  • Takeda's Commitment to Dengue Prevention (Video)

  • Introduction – M.M. Nordin

  • Dengue Situation in Malaysia: Epidemiology, Morbidity and Mortality – M. Mustafa

  • Characterization of Immune Responses Elicited by Takeda's Tetravalent Dengue Vaccine – H. Dean

  • Update on Takeda's Tetravalent Dengue Vaccine Clinical Development Program – G. Dubin

  • Summary & Closing

 

Vaccination: Ways and Means to a Vital Healthy Aging

Room: Conference Hall 3

Friday, February 21, 2020, 12:30 – 13:45 hrs

(Organized and Sponsored by GSK)
 

  • Opening and Introduction – A. Kamarulzaman (University of Malaya, Malaysia)

  • Aging of the Immune System: Impact on Disease and Vaccination – P. Buchy (GSK Vaccines)

  • Safeguarding the Vitality in Older Adults and Risk Groups through Vaccination – S. Badur (GSK Vaccines) & M. Nissen (GSK Vaccines)

  • Vaccines' Future for Our Future – P. Buchy (GSK Vaccines)

  • Question & Answers

Bridging the Gap: Why Diagnostics in Antimicrobial Stewardship

Room: Banquet Hall

Friday, February 21, 2020, 14:00 – 15:30 hrs

(Organized and Sponsored by bioMérieux)

  • AMS in Asia: An Audible Perspective – A. Apisarnthanarak (Thailand)

  • G-PPS (Global-Point Prevalence Survey): A Key Example of Surveillance in Rational Antimicrobial Usage – K. Marimuthu (Singapore)

  • The Role of Rapid Diagnostics in AMS – P. Lee (Taiwan)

 

Addressing the Changing Needs of Community Acquired Pneumonia Management

Room: Banquet Hall

Friday, February 21, 2020, 17:15 – 18:15 hrs

(Organized and Sponsored by Pfizer Anti-Infectives)
 

  • Opening Remarks - Speaker TBD

  • Addressing the Changing Needs of CAP Management - P. Montravers (France)

  • Questions & Answers

 

 

 

Saturday, February 22, 2020

......................................................................................................................................................................

 

 

Burden of Pneumococcal and Meningococcal Diseases Among Adults & Role of Vaccination Programs

Room: Banquet Hall

Saturday, February 22, 2020, 10:30 – 12:00 hrs

(Organized and Sponsored by Pfizer Vaccines)
 

  • Welcome & Introductions – P. Periasamy

  • Burden of Pneumococcal Disease & Role of Vaccination Strategies Among Adults – C. Feldman

  • Epidemiology and Burden of Meningococcal Disease Among Risk Groups – A.R. Abdul Muttalif

  • Question & Answers

20/20 Vision on Adult Vaccination (Panel Discussion) 

Room: Conference Hall 1

Saturday, February 22, 2020, 12:30 – 13:45 hrs

(Organized and Sponsored by Sanofi Pasteur)

 

  • Vaccination and its impact on mankind have come a long way. 225 years have passed since the day Dr Edward Jenner performed his first vaccination in humans against smallpox. Even as we enter a new era in 2020, vaccination coverage rates among adults are still far from optimum despite the availability and access to vaccines. The burden of vaccine preventable diseases in adults and the impact of vaccination to this important group are currently underestimated. Having a “20/20 vision” on adult vaccination should be a priority for healthcare practitioners to be able to effectively advocate adult vaccination especially among the at-risk groups. The expert panel, consisting of leading global experts of infectious diseases, aims to put the pieces together to give clarity on the current gaps, goals and practical steps to bring adult vaccination to a new level.

 

Monkeypox, An Emerging Threat?

Room: Conference Hall 3

Saturday, February 22, 2020, 12:30 – 13:45 hrs

(Organized and Sponsored by Bavarian Nordic)

Moderator: Brett Petterson

 

  • Welcome and Opening Remarks – B. Petersen

  • Topic 1: What is Monkeypox? – A. Ogunleye, A. McCollum, M. Iroezindu, P. Silvera
    - Overview of Monkeypox

  • Topic 2: Outbreaks of Monkeypox: How, Where, and Global ImpactA. Ogunleye, A. McCollum, M. Iroezindu, P. Silvera
    - What countries have reported Monkeypox?
    - What do we know about the spread of Monkeypox?
    - What is the impact of global travel on the spread of Monkeypox?
    - What are the grey areas in the spread of Monkeypox?
    - Challenges and successes in Monkeypox detection and control

  • Topic 3: Vaccine Option for Prevention
    - JYNNEOS, a New FDA-Approved Vaccine for Treatment of Human Smallpox and Monkeypox – Supporting Preclinical Data – P. Silvera

  • Topic 4: Prevention and Awareness – Keys to Control the SpreadA. Ogunleye, A. McCollum, M. Iroezindu, P. Silvera
    - Prevention and Treatment
    - The importance of awareness
    - Steps toward prevention and control of Monkeypox (including the role of research, surveillance and countermeasures)

  • Closing Remarks – B. Petersen